Archives
-
From Acid Mucin Signal to Translational Evidence
2026-09-22
A mechanistic and strategic guide to using the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5 for acid mucin visualization, chondrogenic differentiation staining, and better translational decision-making.
-
IGF2BP3–FZD1/7 Drives Carboplatin Resistance
2026-09-22
This 2025 Cancer Letters study identifies an IGF2BP3–FZD1/7 regulatory axis that maintains stem-like properties and carboplatin resistance in triple-negative breast cancer. Its findings connect m6A-dependent RNA stabilization, β-catenin signaling, and homologous recombination repair, while supporting FZD1/7 inhibition as a strategy for sensitizing TNBC cancer stem-like cells.
-
Masitinib (AB1010) KIT/PDGFR Workflow Guide
2026-09-21
Masitinib (AB1010) provides a DMSO-compatible research reagent for studying KIT and PDGFRα/β signaling, including cancer biology, mastocytosis research, and inflammatory cell models. It should not be treated as a clinical treatment recommendation or used in workflows requiring aqueous or ethanol solubility without additional formulation validation.
-
Amphotericin B: From Membrane Pores to Translation
2026-09-21
A translational perspective on Amphotericin B that connects fungal membrane sterol interaction, immune signaling, protoplast-based validation, and exploratory prion models with practical guidance for rigorous study design.
-
Dye Models for Small Biopsies in Pathology
2026-09-20
The reference study evaluates whether visible dye marking can reduce the risk of losing or overlooking very small biopsy fragments during routine tissue processing. Merbromin, hematoxylin, and Alcian blue improved tissue visibility, but hematoxylin was favored because it combined visibility with lower toxicity and no reported interference during diagnostic slide review.
-
FGF19–ELF4–SRC Circuit in Colorectal Cancer Metastasis
2026-09-19
This study identifies an FGF19–ERK1/2–SP1–ELF4 signaling axis that drives colorectal cancer metastasis by activating FGFR4 and SRC transcription. Its combination of clinical expression analysis, mechanistic transcriptional assays, and metastatic models supports dual pathway inhibition as a potential strategy, while also defining important limits for translating SRC-inhibitor data across research contexts.
-
MitMAB: Causal Mapping of EV Uptake
2026-09-18
MitMAB enables mechanistic analysis of dynamin-dependent extracellular-vesicle uptake in polarized intestinal models. This article moves beyond simple inhibition assays to show how polarity, tissue region, assay controls, and orthogonal readouts determine what an uptake result actually means.
-
Mitochondrial Shape as a Switch for Bone Repair
2026-09-18
A mechanistic perspective on how PFKM suppression, ER–mitochondria contacts, calcium signaling, and DRP1 remodeling may coordinate osteogenesis—and how ER-focused live-cell imaging can strengthen translational validation.
-
Ozone, Efferocytosis, and Neuropathic Pain
2026-09-17
Ruan and colleagues report that ozone reduces neuropathic pain in a chronic constriction injury model by enhancing macrophage efferocytosis through the AMPK/Gas6-MerTK/SOCS3 pathway. The study links apoptotic-cell clearance to suppression of neuroinflammation and provides a mechanistic framework for investigating immunomodulatory approaches to pain.
-
Olsalazine Sodium in Cancer and Transport Studies
2026-09-17
Olsalazine Sodium combines mesalamine-dimer chemistry with potent LTB4 chemotaxis inhibition for colorectal cancer, macrophage inflammation, and xenobiotic-clearance workflows. This guide translates its formulation constraints and emerging mosquito transport data into practical assay design, optimization, and troubleshooting decisions.
-
LNP mRNA Bleb Structures Improve Transfection Potency
2026-09-16
The reference study shows that mRNA-rich bleb structures in lipid nanoparticles can be induced by formulation conditions, including high-concentration pH 4 sodium citrate, even when the ionizable lipid is not intrinsically highly active. These structures were associated with improved in vitro and in vivo expression, apparently in part because they preserved encapsulated mRNA integrity rather than simply increasing intracellular delivery.
-
Gasdermin C Drives Stemness and Immune Evasion in PDAC
2026-09-16
A 2024 Advanced Science study identifies GSDMC as a noncanonical regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion. The work links ADAM17-dependent cleavage and nuclear GSDMC activity to CXCL9-mediated immune remodeling, suggesting that blocking this pathway may improve responses to KRASG12D inhibition and PD-1 checkpoint blockade.
-
β-Elemene: From AMPK Insight to Translational Strategy
2026-09-15
A translational framework for using β-Elemene and Levo-β-elemene to connect AMPK-centered adipogenesis findings with apoptosis, inflammation, neuroprotection, and PI3K/AKT/mTOR pathway research.
-
Topotecan: Pharmacology, Mechanism, and Clinical Evidence
2026-09-15
The 1999 review by Kollmannsberger and colleagues established topotecan as a clinically relevant, water-soluble topoisomerase I inhibitor with a distinctive DNA-damaging mechanism. Its analysis connected lactone chemistry, pharmacokinetics, dose-limiting myelosuppression, and early clinical activity in ovarian cancer, small-cell lung cancer, and other malignancies.
-
Danazol: From Steroid Perturbation to Model Validity
2026-09-14
Danazol and Danocrine are valuable endocrine research tools, but their interpretation depends on separating receptor activity, steroidogenesis, and hypothalamic responses. This article examines a 2025 rat study to show how model choice and endpoint selection improve mechanistic assay validity.